Finnrick, an independent testing programme, publishes 5 assays for Pinecrest Peptide, and all 3 that it grades met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation). Most recent assay 23 Apr 2026.
Pinecrest Peptide listed by Finnrick as "Trading". Source: Finnrick, https://www.finnrick.com/vendors/pinecrest-peptide.
Pinecrest Peptide is listed as active.
| Product | Assays | Result |
|---|---|---|
| Retatrutide | 5 | 3 passed, 0 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Vendor type | Research-use supplier |
These details were read from Pinecrest Peptide's own website on 2026-08-10. Pages consulted:
Pinecrest Peptide is listed as active and we hold 5 Finnrick assays (3 passing, 0 failing its purity threshold). That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 5 assays for Pinecrest Peptide, and all 3 that it grades met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation). Most recent assay 23 Apr 2026.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: Pink Pony Peptides Review, Planet Peptide Review, Platinum Cryo Peptides Review.